Comparison of OHR Pharmaceutical Inc. (OHRP) and Ophthotech Corporation (NASDAQ:OPHT)

Both OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Ophthotech Corporation (NASDAQ:OPHT) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OHR Pharmaceutical Inc. N/A 0.00 9.98M -3.54 0.00
Ophthotech Corporation N/A 0.00 63.09M -1.40 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of OHR Pharmaceutical Inc. and Ophthotech Corporation.


Table 2 demonstrates the return on assets, return on equity and net margins of OHR Pharmaceutical Inc. and Ophthotech Corporation.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical Inc. 0.00% -71.5% -66.8%
Ophthotech Corporation 0.00% 688.2% 97.3%

Volatility and Risk

OHR Pharmaceutical Inc. is 17.00% more volatile than Standard and Poor’s 500 due to its 1.17 beta. Ophthotech Corporation’s 51.00% more volatile than Standard and Poor’s 500 volatility due to the stock’s 1.51 beta.


OHR Pharmaceutical Inc.’s Current Ratio is 5.4 while its Quick Ratio is 5.4. On the competitive side is, Ophthotech Corporation which has a 13 Current Ratio and a 13 Quick Ratio. Ophthotech Corporation is better positioned to pay off short and long-term obligations compared to OHR Pharmaceutical Inc.

Insider & Institutional Ownership

Roughly 12.7% of OHR Pharmaceutical Inc. shares are owned by institutional investors while 65.6% of Ophthotech Corporation are owned by institutional investors. About 8.89% of OHR Pharmaceutical Inc.’s share are owned by insiders. Insiders Competitively, owned 0.2% of Ophthotech Corporation shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OHR Pharmaceutical Inc. 3.29% -17.91% -31.21% -43.18% -50.81% 27.91%
Ophthotech Corporation 6.85% 23.81% -12.36% -38.82% -42.86% 30%

For the past year OHR Pharmaceutical Inc. has weaker performance than Ophthotech Corporation


On 6 of the 6 factors Ophthotech Corporation beats OHR Pharmaceutical Inc.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.